Search

Your search keyword '"Dyal, Leanne"' showing total 47 results

Search Constraints

Start Over You searched for: Author "Dyal, Leanne" Remove constraint Author: "Dyal, Leanne"
47 results on '"Dyal, Leanne"'

Search Results

2. The effect of dulaglutide on stroke: an exploratory analysis of the REWIND trial

3. Direct Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation: Patient-Level Network Meta-Analyses of Randomized Clinical Trials With Interaction Testing by Age and Sex

4. Safety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin

5. Pantoprazole to Prevent Gastroduodenal Events in Patients Receiving Rivaroxaban and/or Aspirin in a Randomized, Double-Blind, Placebo-Controlled Trial

8. Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial

9. Rivaroxaban for Prevention of Covert Brain Infarcts and Cognitive Decline: The COMPASS MRI Substudy

10. Total cardiovascular or fatal events in people with type 2 diabetes and cardiovascular risk factors treated with dulaglutide in the REWIND trail: a post hoc analysis

12. A hybrid automated event adjudication system for clinical trials

13. Direct Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation: Patient-Level Network Meta-Analyses of Randomized Clinical Trials With Interaction Testing by Age and Sex

14. sj-docx-1-ctj-10.1177_17407745221149222 – Supplemental material for A hybrid automated event adjudication system for clinical trials

16. A hybrid automated event adjudication system for clinical trials.

18. Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes

19. Low-dose rivaroxaban and aspirin among patients with peripheral artery disease: a meta-analysis of the COMPASS and VOYAGER trials

20. Cardiovascular consequences of discontinuing low-dose rivaroxaban in people with chronic coronary or peripheral artery disease

21. A post hoc analysis

22. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial

23. Rivaroxaban and Aspirin in Patients With Symptomatic Lower Extremity Peripheral Artery Disease

24. An exploratory analysis of the REWIND trial

25. Additional file 1 of Total cardiovascular or fatal events in people with type 2 diabetes and cardiovascular risk factors treated with dulaglutide in the REWIND trail: a post hoc analysis

26. Similar cardiovascular outcomes in patients with diabetes and established or high risk for coronary vascular disease treated with dulaglutide with and without baseline metformin

27. Effect of Insulin Glargine and n-3FA on Carotid Intima-Media Thickness in People With Dysglycemia at High Risk for Cardiovascular Events: The Glucose Reduction and Atherosclerosis Continuing Evaluation Study (ORIGIN-GRACE)

30. Effect of Telmisartan on Renal Outcomes: A Randomized Trial

31. Similar cardiovascular outcomes in patients with diabetes and established or high risk for coronary vascular disease treated with dulaglutide with and without baseline metformin.

32. Estimating individual lifetime benefit and bleeding risk of adding rivaroxaban to aspirin for patients with stable cardiovascular disease: results from the COMPASS trial

33. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial

34. Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial

38. Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial

39. External applicability of the COMPASS trial: an analysis of the reduction of atherothrombosis for continued health (REACH) registry

41. Characteristics associated with maintenance of mean A1C<6.5% in people with dysglycemia in the ORIGIN trial

42. External applicability of the COMPASS trial: an analysis of the reduction of atherothrombosis for continued health (REACH) registry.

43. n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia

45. Estimating individual lifetime benefit and bleeding risk of adding rivaroxaban to aspirin for patients with stable cardiovascular disease: results from the COMPASS trial.

46. n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia.

47. Telmisartan, ramipril, or both in patients at high risk for vascular events.

Catalog

Books, media, physical & digital resources